The Paisa Kids Study establishes a longitudinal cohort of youth from the Paisa region of Colombia to clarify clinical, neurobehavioral, genetic, and environmental profiles associated with later Serious Mental Illness (SMI). The study focuses on transdiagnostic risk pathways that lead to schizophrenia, bipolar disorder, and severe depression and aims to distinguish shared from disorder-specific developmental trajectories. The investigators plan a target cohort of 3,000 participants aged 6–15 years and intend to combine multidomain phenotyping with genomic data and longitudinal electronic medical record (EMR) follow-up.
Recruitment enriches the cohort for transdiagnostic SMI risk using two principal streams. High SMI-risk youth are eligible if they have either a first- or second-degree adult relative diagnosed with SMI or if they themselves have a psychiatric diagnosis identified in EMRs that are associated with later SMI. Lower-risk participants are youth whose relatives do not have a diagnosed SMI. This design supports comparison between youth with elevated familial or EMR-based risk and a lower-risk comparator group drawn from the same population.
Baseline evaluations capture multiple domains. Core measures include psychiatric and developmental history, standardized neurobehavioral functioning assessments, and structured recording of environmental exposures including adverse childhood experiences (ACEs). Biological data collection includes genome-wide genotyping. The study leverages existing psychiatric EMRs to provide longitudinal clinical follow-up and outcome ascertainment over time.
At the time of this initial characterization, 2,384 participants had been enrolled. The cohort mean age was 11.2 years and 45.0% of participants were female. Of the enrolled sample, 2,211 participants were recruited as high SMI-risk and 173 as lower SMI-risk. The report notes that 73.2% of participants met criteria for a history of one or more psychiatric disorders at baseline.
Logistic regression analyses comparing recruitment streams identified elevated rates of several baseline psychiatric diagnoses among high-risk versus lower-risk youth. Specifically, rates of depressive disorders, anxiety disorders, attention-deficit/hyperactivity disorder (ADHD), and oppositional defiant disorder (ODD) were higher in the high SMI-risk group. The high-risk group also exhibited higher rates of several adverse childhood experiences (ACEs) compared with the lower-risk group. The article provides these group-level contrasts to characterize early clinical and environmental differences in this transdiagnostically enriched cohort.
The study protocol complied with Colombian regulations for human subjects research and the Declaration of Helsinki. Ethical approvals were granted by the research ethics committees at the University of Washington and HOMO hospital. The authors state that all required participant consents and institutional approvals were obtained. Data generated by the study will be available to approved users through the NIH Data Archive (dataset DOI provided in the source). Funding acknowledged includes the National Institute of Mental Health (R01MH127165). The report is presented as a medRxiv preprint and has not been peer reviewed; it was posted October 7, 2026.
By integrating clinical phenotyping across psychiatric and developmental domains, standardized neurobehavioral testing, environmental exposure measurement, genome-wide genotyping, and longitudinal EMR linkage, the Paisa Kids cohort is positioned to address questions about early markers of risk and resilience for SMI. The transdiagnostic enrichment strategy allows investigators to probe shared versus disorder-specific early trajectories and to study gene–environment interactions in a defined regional population.
Future work from this cohort will depend on continued enrollment to the target sample of 3,000 youth, ongoing follow-up via EMR and prospective assessments, and analyses that combine genomic and phenotype data. As the current report is an initial characterization from a preprint, additional peer-reviewed publications will be needed to confirm and extend these baseline findings. Data sharing through the NIH Data Archive should enable external researchers to validate and build upon the cohort results.
Note: This summary is based solely on information reported in the cited medRxiv preprint. The source document is a preprint and had not been peer reviewed at the time of posting.